Quantcast

Latest Enbrel Stories

2011-05-25 07:00:00

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe...

2011-02-04 08:00:00

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology (AAD) meeting in New Orleans, La. "At least half of people with...

2010-12-07 08:15:00

BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor (TNF)-alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis (RA) patients, outpacing Abbott's Humira in the first three lines of treatment. According to the upcoming Treatment Algorithms in Rheumatoid Arthritis report, two percent of newly...

2010-12-01 07:00:00

BURLINGTON, Mass., Dec. 1, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although Amgen/Pfizer/Stiefel's Enbrel will remain the most-prescribed first-line biologic for moderate-to-severe psoriasis, it will lose market share at this line of therapy to agents in the IL-12/IL-23 inhibitors drug class, namely Centocor Ortho Biotech/Janssen-Cilag's Stelara. Surveyed U.S. dermatologists...

2010-11-08 07:08:00

ATLANTA, Nov. 8, 2010 /PRNewswire/ -- Patients with active moderate to severe rheumatoid arthritis (RA) inadequately responding to either etanercept (Enbrel(®)) or adalimumab (Humira(®)) and who were actively switched to REMICADE(®) (infliximab) demonstrated significant improvement from baseline at week 10, and sustained response through week 26 in an open label study. These week 26 results from the RESTART study were presented for the...

2010-11-06 16:00:00

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010 /PRNewswire/ -- Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil's experience with his diagnosis of psoriatic arthritis and treatment with Enbrel® (etanercept), and to encourage patients with similar symptoms to visit their doctor for proper assessment and care. "This partnership with Amgen and Pfizer is...

2010-11-02 06:00:00

NEW YORK, Nov. 2, 2010 /PRNewswire-FirstCall/ -- Third-Quarter 2010 Revenues of $16.2 Billion Third-Quarter 2010 Adjusted Diluted EPS((1)) of $0.54; Reported Diluted EPS((2)) of $0.11 Tightens Ranges for 2010 Financial Guidance Components, Increases Range for Adjusted Diluted EPS((1)) and Reduces Range for Reported Diluted EPS((2)); Reaffirms 2012 Financial Targets Advances Strategic Priorities with Agreement to Acquire King Pharmaceuticals, Inc., Acquisition of FoldRx, Alliance with...

2010-09-22 07:00:00

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while Amgen/Stiefel/Pfizer's Enbrel is the most popular biologic across all lines of therapy for psoriasis treatment in newly diagnosed patients, Abbott's Humira is gaining increasing use as a first-line biologic at Enbrel's expense. According to the new report entitled Treatment Algorithms in Psoriasis, dermatologists'...

2010-08-03 06:00:00

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Second-Quarter 2010 Revenues of $17.3 Billion Second-Quarter 2010 Reported Diluted EPS((1)) of $0.31, Adjusted Diluted EPS((2)) of $0.62 Reaffirms 2010( )Financial Guidance and 2012 Financial Targets( ) Strong Quarterly Performance Reflects More Balanced Business Mix and Product Portfolio ($ in millions, except per share amounts) Second-Quarter Year-to-Date --------------...

2010-03-23 07:00:00

WALTHAM, Mass., March 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists view Abbott/Eisai's Humira as the most efficacious therapy for the treatment of moderate to severe psoriasis. Thirty-two percent of surveyed dermatologists selected Humira as the most efficacious, followed by Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade (29 percent). The current sales...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related